Citations
Key articles
National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program. Expert panel report 3: Guidelines for the diagnosis and management of asthma. August 2007. http://www.nhlbi.nih.gov (last accessed 15 January 2013).
Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184:602-615.
Petsky HL, Cates CJ, Lasserson TJ, et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax. 2012;67:199-208.
Joos S, Miksch A, Szecsenyi J, et al. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. Thorax. 2008;63:453-462.
Rodrigo GJ, Moral VP, Marcos LG, et al. Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma. A systematic review. Pulm Pharmacol Ther. 2009;22:9-19.
Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med. 2010;363:1715-1726.
Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest. 2011;139:28-35.
Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev. 2012;(5):CD002314.
Ducharme FM, Lasserson TJ, Cates CJ. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database Syst Rev. 2011;(5):CD003137.
Masoli M, Weatherall M, Holt S, et al. Inhaled fluticasone propionate and adrenal effects in adult asthma: systematic review and meta-analysis. Eur Respir J. 2006;28:960-967.
Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365:1088-1098.
Reference articles
1. National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program. Expert panel report 3: Guidelines for the diagnosis and management of asthma. August 2007. http://www.nhlbi.nih.gov (last accessed 15 January 2013).
2. Lugogo NL, Kraft M. Epidemiology of asthma. Clin Chest Med. 2006;27:1-15.
3. National Heart, Lung, and Blood Institute. Clinical practice guidelines: expert panel report 2: guidelines for the diagnosis and management of asthma. 1997. http://www.nhlbi.nih.gov (last accessed 15 January 2013).
4. Mintz M. Asthma update: part I. Diagnosis, monitoring, and prevention of disease progression. Am Fam Physician. 2004;70:893-898.
5. Ober C, Hoffjan S. Asthma genetics 2006: the long and winding road to gene discovery. Genes Immun. 2006;7:95-100.
6. Holgate ST, Yang Y, Haitchi HM, et al. The genetics of asthma: ADAM33 as an example of a susceptibility gene. Proc Am Thorac Soc. 2006;3:440-443.
7. Gao J, Shan G, Sun B, et al. Association between polymorphism of tumour necrosis factor alpha-308 gene promoter and asthma: a meta-analysis. Thorax. 2006;61:466-471.
8. Ober C. HLA-G: an asthma gene on chromosome 6p. Immunol Allergy Clin North Am. 2005;25:669-679.
9. Holgate ST, Davies DE, Powell RM, et al. ADAM33: a newly identified gene in the pathogenesis of asthma. Immunol Allergy Clin North Am. 2005;25:655-668.
10. Zimmermann N, King NE, Laporte J, et al. Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J Clin Invest. 2003;111:1863-1874.
11. Vercelli D. Genetic polymorphism in allergy and asthma. Curr Opin Immunol. 2003;15:609-613.
12. Shin HD, Kim LH, Park BL, et al. Association of Eotaxin gene family with asthma and serum total IgE. Hum Mol Genet. 2003;12:1279-1285.
13. Sayers I, Barton S, Rorke S, et al. Promoter polymorphism in the 5-lipoxygenase (ALOX5) and 5-lipoxygenase-activating protein (ALOX5AP) genes and asthma susceptibility in a Caucasian population. Clin Exp Allergy. 2003;33:1103-1110.
14. Howard TD, Postma DS, Jongepier H, et al. Association of a disintegrin and metalloprotease 33 (ADAM33) gene with asthma in ethnically diverse populations. J Allergy Clin Immunol. 2003;112:717-722.
15. Tsai HJ, Shaikh N, Kho JY, et al. Beta 2-adrenergic receptor polymorphisms: pharmacogenetic response to bronchodilator among African American asthmatics. Hum Genet. 2006;119:547-557.
16. Singh AM, Busse WW. Asthma exacerbations. 2: Aetiology. Thorax. 2006;61:809-816.
17. Wark PA, Gibson PG. Asthma exacerbations. 3: Pathogenesis. Thorax. 2006;61:909-915.
18. Velissariou IM, Papadopoulos NG. The role of respiratory viruses in the pathogenesis of pediatric asthma. Pediatr Ann. 2006;35:637-642.
19. Phipatanakul W. Environmental factors and childhood asthma. Pediatr Ann. 2006;35:646-656.
20. Oliver BG, Johnston SL, Baraket M, et al. Increased proinflammatory responses from asthmatic human airway smooth muscle cells in response to rhinovirus infection. Respir Res. 2006;7:71.
21. Blakey J, Halapi E, Bjornsdottir US, et al. Contribution of ADAM33 polymorphisms to the population risk of asthma. Thorax. 2005;60:274-276.
22. Holgate ST, Davies DE, Rorke S, et al. ADAM 33 and its association with airway remodeling and hyperresponsiveness in asthma. Clin Rev Allergy Immunol. 2004;27:23-34.
23. Raby BA, Silverman EK, Kwiatkowski DJ, et al. ADAM33 polymorphisms and phenotype associations in childhood asthma. J Allergy Clin Immunol. 2004;113:1071-1078.
24. Halapi E, Hakonarson H. Recent development in genomic and proteomic research for asthma. Curr Opin Pulm Med. 2004;10:22-30.
25. Holgate ST, Davies DE, Murphy G, et al. ADAM 33: just another asthma gene or a breakthrough in understanding the origins of bronchial hyperresponsiveness? Thorax. 2003;58:466-469.
26. Shapiro SD, Owen CA. ADAM-33 surfaces as an asthma gene. N Engl J. 2002;347:936-938.
27. Meurer JR, Lustig JV, Jacob HJ. Genetic aspects of the etiology and treatment of asthma. Pediatr Clin North Am. 2006;53:715-725.
28. Lilly CM. Diversity of asthma: evolving concepts of pathophysiology and lessons from genetics. J Allergy Clin Immunol. 2005;115:S526-S531.
29. Raby BA, Silverman EK, Lazarus R, et al. Chromosome 12q harbors multiple genetic loci related to asthma and asthma-related phenotypes. Hum Mol Genet. 2003;12:1973-1979.
30. Aoki T, Hirota T, Tamari M, et al. An association between asthma and TNF-308G/A polymorphism: meta-analysis. J Hum Genet. 2006;51:677-685.
31. Di Somma C, Charron D, Deichmann K, et al. Atopic asthma and TNF-308 alleles: linkage disequilibrium and association analyses. Hum Immunol. 2003;64:359-365.
32. Canonica GW. Treating asthma as an inflammatory disease. Chest. 2006;130:21S-28S.
33. Ballow M. Biologic immune modifiers: trials and tribulations - are we there yet? J Allergy Clin Immunol. 2006;118:1209-1215.
34. Boyce JA. Asthma 2005-2006: bench to bedside. J Allergy Clin Immunol. 2006;118:582-586.
35. Cockcroft DW, Davis BE. Mechanisms of airway hyperresponsiveness. J Allergy Clin Immunol. 2006;118:551-559.
36. Zeitz HJ. Bronchial asthma, nasal polyps, and aspirin sensitivity: Samter's syndrome. Clin Chest Med. 1988;9:567-576.
37. Shore SA. Obesity and asthma: possible mechanisms. J Allergy Clin Immunol. 2008;121:1087-1093.
38. King GG, Brown NJ, Diba C, et al. The effects of body weight on airway calibre. Eur Respir J. 2005;25:896-901.
39. Mastronarde JG, Anthonisen NR, Castro M, et al. Efficacy of esomeprazole for treatment of poorly controlled asthma. N Engl J Med. 2009;360:1487-1499.
40. Cockcroft DD. Direct and indirect challenges in the clinical assessment of asthma. Ann Allergy Asthma Immunol. 2009;103:363-369.
41. Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184:602-615.
42. Powell H, Murphy VE, Taylor DR, et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet. 2011;378:983-990.
43. Petsky HL, Cates CJ, Lasserson TJ, et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax. 2012;67:199-208.
44. Carden KA, Boiselle PM, Waltz DA, et al. Tracheomalacia and tracheobronchomalacia in children and adults. An in-depth review. Chest. 2005;127:984-1005.
45. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180:59-99.
46. Passalacqua G, Durham SR. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol. 2007;119:881-891.
47. Joos S, Miksch A, Szecsenyi J, et al. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. Thorax. 2008;63:453-462.
48. Rodrigo GJ, Moral VP, Marcos LG, et al. Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma. A systematic review. Pulm Pharmacol Ther. 2009;22:9-19.
49. Cates CJ, Lasserson TJ. Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev. 2009;(2):CD007313.
50. Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med. 2010;363:1715-1726.
51. Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest. 2011;139:28-35.
52. Bardelas J, Figliomeni M, Kianifard F, et al. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma. J Asthma. 2012;49:144-152.
53. Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011;154:573-582.
54. Lasserson TJ, Cates CK, Jones AB, et al. Fluticasone versus 'extrafine' HFA beclomethasone dipropionate for chronic asthma in adults and children. Cochrane Database Syst Rev. 2006;(2):CD005309.
55. Cates CJ, Bestall J, Adams N. Holding chambers versus nebulisers for inhaled steroids in chronic asthma. Cochrane Database Syst Rev. 2006;(1):CD001491.
56. Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev. 2012;(5):CD002314.
57. Ducharme FM, Lasserson TJ, Cates CJ. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database Syst Rev. 2011;(5):CD003137.
58. Tee AK, Koh MS, Gibson PG, et al. Long-acting beta2-agonists versus theophylline for maintenance treatment of asthma. Cochrane Database Syst Rev. 2007;(3):CD001281.
59. American Lung Association Asthma Clinical Research Centers. Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. Am J Respir Crit Care Med. 2007;175:235-242.
60. Masoli M, Weatherall M, Holt S, et al. Inhaled fluticasone propionate and adrenal effects in adult asthma: systematic review and meta-analysis. Eur Respir J. 2006;28:960-967.
61. Lipworth BJ, Kaliner MA, LaForce CF, et al. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. An Allergy Asthma Immunol. 2005;94:465-472.
62. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360:985-993.
63. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360:973-84.
64. Tourangeau LM, Kavanaugh A, Wasserman SI. The role of monoclonal antibodies in the treatment of severe asthma. Ther Adv Resp Dis. 2011;5:183-194.
65. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365:1088-1098.
66. Erin EM, Leaker BR, Nicholson GC, et al. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med. 2006;174:753-762.
67. Cazzola M, Polosa R. Anti-TNF-alpha and Th1 cytokine-directed therapies for the treatment of asthma. Curr Opin Allergy Clin Immunol. 2006;6:43-50.
68. Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNF alpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax. 2005;60:1012-1018.
69. Antoniu SA. Etanercept for refractory asthma therapy. Expert Opin Invest Drugs. 2006;15:1279-1281.
70. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med. 2006;354:697-708.
71. Castro M, Rubin AS, Laviolette M, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2010;181:116-124.
72. National Institute for Health and Clinical Excellence. Bronchial thermoplasty for severe asthma. January 2012. http://www.nice.org.uk (last accessed 15 January 2013).
73. Wu Q, Xing Y, Zhou X, et al. Meta-analysis of the efficacy and safety of bronchial thermoplasty in patients with moderate-to-severe persistent asthma. J Int Med Res. 2011;39:10-22.
74. Sears MR, Greene JM, Willan AR, et al. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. N Engl J Med 2003;349:1414-1422.
75. Phelan PD, Robertson CF, Olinksy A. The Melbourne Asthma Study: 1964-1999. J Allergy Clin Immunol. 2002;109:189-194.
76. James AL, Palmer LJ, Kicic E, et al. Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking. Am J Respir Crit Care Med. 2005;171: 109-114.
77. James AL, Wenzel S. Clinical relevance of airway remodelling in airway diseases. Eur Respir J. 2007;30:134-155.
78. Bai TR, Vonk JM, Postma DS, Boezen HM. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J. 2007;30:452-456.
79. Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev. 2008;(3):CD006363.
80. Schreck DM. Asthma pathophysiology and evidence-based treatment of severe exacerbations. Am J Health Syst Pharm. 2006;63:S5-S13.
81. O'Byrne PM, Pedersen S, Lamm CJ, et al. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med. 2009;179:19-24.
82. Slade DJ, Kraft M. Airway remodeling from bench to bedside: current perspectives. Clin Chest Med. 2006;27:71-85.
83. Mascia K, Haselkorn T, Deniz YM, et al. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2005;116:970-975.
84. Lee JY, Park SW, Chang HK, et al. A disintegrin and metalloproteinase 33 protein in patients with asthma: Relevance to airflow limitation. Am J Respir Crit Care Med. 2006;173:729-935.
85. Carlsen KH, Anderson SD, Bjermer L, et al. Treatment of exercise-induced asthma, respiratory and allergic disorders in sports and the relationship to doping: part II of the report from the Joint Task Force of European Respiratory Society (ERS) and European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA(2)LEN. Allergy. 2008;63:492-505.
86. Thien FC, De Luca S, Woods RK, et al. Dietary marine fatty acids (fish oil) for asthma in adults and children. Cochrane Database Syst Rev. 2002;(3):CD001283.
87. Bateman ED, Kornmann O, Schmidt P, et al. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol. 2011;128:315-322.
